S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

$5.26
-0.22 (-4.01%)
(As of 02:10 PM ET)
Today's Range
$5.23
$5.66
50-Day Range
$4.55
$5.48
52-Week Range
$1.86
$5.79
Volume
126,372 shs
Average Volume
260,164 shs
Market Capitalization
$276.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Lyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
163.7% Upside
$14.00 Price Target
Short Interest
Healthy
0.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Lyra Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.32) to ($1.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.94 out of 5 stars

Medical Sector

354th out of 958 stocks

Surgical & Medical Instruments Industry

43rd out of 97 stocks


LYRA stock logo

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Stock Price History

LYRA Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
15 Unhappiest States in the US
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
Lyra Therapeutics Insider Ups Holding By 11% During Year
What 4 Analyst Ratings Have To Say About Lyra Therapeutics
H.C. Wainwright Keeps Their Buy Rating on Lyra Therapeutics (LYRA)
See More Headlines
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/29/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$15.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+150.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-55,280,000.00
Net Margins
-4,340.06%
Pretax Margin
-4,336.19%

Debt

Sales & Book Value

Annual Sales
$1.36 million
Book Value
$2.54 per share

Miscellaneous

Free Float
43,407,000
Market Cap
$294.34 million
Optionable
Optionable
Beta
0.15
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Harlan W. Waksal M.D. (Age 71)
    Executive Chairman
    Comp: $214.06k
  • Dr. Maria Palasis Ph.D. (Age 59)
    CEO, President & Director
    Comp: $865.15k
  • Dr. Richard Nieman M.D. (Age 61)
    Chief Medical Officer
    Comp: $606.7k
  • Dr. Carmichael S. Roberts Jr. (Age 56)
    Ph.D., Co-Founder
  • Mr. Jason Cavalier (Age 51)
    CFO, Treasurer & Secretary
    Comp: $464.11k
  • Mr. Ray Knox
    Vice President of Operations
  • Dr. John E. Bishop Ph.D. (Age 62)
    Chief Technology Officer
  • Ms. Ellen Cavaleri
    Senior Vice President of Investor Relations & Communications
  • Mr. Ronan P. O'Brien J.D. (Age 51)
    Chief Legal Officer
  • Ms. Corinne Noyes (Age 56)
    Senior Vice President of Commercial Strategy & Market Development
    Comp: $426.73k














LYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings
or view top-rated stocks.

What is Lyra Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 12 month price objectives for Lyra Therapeutics' shares. Their LYRA share price targets range from $12.00 to $15.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 163.7% from the stock's current price.
View analysts price targets for LYRA
or view top-rated stocks among Wall Street analysts.

How have LYRA shares performed in 2024?

Lyra Therapeutics' stock was trading at $5.24 at the start of the year. Since then, LYRA stock has increased by 1.3% and is now trading at $5.31.
View the best growth stocks for 2024 here
.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 185,400 shares, an increase of 43.5% from the January 31st total of 129,200 shares. Based on an average daily trading volume, of 236,700 shares, the short-interest ratio is presently 0.8 days.
View Lyra Therapeutics' Short Interest
.

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our LYRA earnings forecast
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.07. The company earned $0.01 million during the quarter. Lyra Therapeutics had a negative trailing twelve-month return on equity of 73.41% and a negative net margin of 4,340.06%. During the same quarter last year, the business posted ($0.49) earnings per share.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vestal Point Capital LP (5.71%), Point72 Asset Management L.P. (5.71%), Armistice Capital LLC (2.07%), Vanguard Group Inc. (2.04%), Parkman Healthcare Partners LLC (1.44%) and Dimensional Fund Advisors LP (0.21%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYRA) was last updated on 2/29/2024 by MarketBeat.com Staff